ICI-85966
Identifiers | |
---|---|
| |
Synonyms | Stilbostat |
CAS Number | 15470-58-3 |
PubChem (CID) | 3037081 |
ChemSpider | 2300916 |
Chemical and physical data | |
Formula | C28H34Cl4N2O4 |
Molar mass | 604.39256 g/mol |
3D model (Jmol) | Interactive image |
| |
|
ICI-85966 (former tentative brand name Stilbostat), also known as diethylstilbestrol bis(di(2-chloroethyl)carbamate), is a synthetic, non-steroidal estrogen and alkylating antineoplastic agent of the stilbestrol group and a cytostatic nitrogen mustard ester of diethylstilbestrol (DES) that was developed for the treatment of breast cancer and prostate cancer but was never marketed.[1][2][3][4][5] It was found to markedly improve the clinical state in approximately 65% of women treated with it for advanced breast cancer in a clinical study.[4]
See also
References
- ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 397. ISBN 978-1-4757-2085-3.
- ↑ Zimel H, Broder D, Zimel A (1973). "[Therapeutic effects of the preparation "Stilbostat" in advanced stages of breast cancer after the menopause]". Stud Cercet Endocrinol (in Romanian). 24 (3): 211–9. PMID 4703920.
- ↑ Görlich M, Heise E (1976). "Contribution to the mechanism of Stilbostat action". Neoplasma. 23 (4): 363–9. PMID 1004653.
- 1 2 Zimel H, Mogos I, Maltezeanu G (1977). "Estimation of StilbostatR treatment efficiency in breast cancer by thermography". Neoplasma. 24 (5): 553–7. PMID 927612.
- ↑ Zimel H, Bocancea D (1974). "Treatment of prostatic carcinoma with Stilbostat". Neoplasma. 21 (1): 101–8. PMID 4596007.
This article is issued from Wikipedia - version of the 11/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.